JP2023551935A - Ｉｌ－７結合タンパク質および医学的療法におけるそれらの使用 - Google Patents

Ｉｌ－７結合タンパク質および医学的療法におけるそれらの使用 Download PDF

Info

Publication number
JP2023551935A
JP2023551935A JP2023533733A JP2023533733A JP2023551935A JP 2023551935 A JP2023551935 A JP 2023551935A JP 2023533733 A JP2023533733 A JP 2023533733A JP 2023533733 A JP2023533733 A JP 2023533733A JP 2023551935 A JP2023551935 A JP 2023551935A
Authority
JP
Japan
Prior art keywords
binding protein
seq
acid sequence
amino acid
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023533733A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551935A5 (https=
Inventor
ヘルベン、ボウマ
エドワード、トーマス、クールストック
デイビッド、ディクソン
ステファニー、ホープリー
アラン、ピーター、ルイス
ジェシカ、リン、ニーゼン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of JP2023551935A publication Critical patent/JP2023551935A/ja
Publication of JP2023551935A5 publication Critical patent/JP2023551935A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023533733A 2020-12-02 2021-11-30 Ｉｌ－７結合タンパク質および医学的療法におけるそれらの使用 Pending JP2023551935A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063120564P 2020-12-02 2020-12-02
US63/120,564 2020-12-02
PCT/EP2021/083465 WO2022117526A1 (en) 2020-12-02 2021-11-30 Il-7 binding proteins and their use in medical therapy

Publications (2)

Publication Number Publication Date
JP2023551935A true JP2023551935A (ja) 2023-12-13
JP2023551935A5 JP2023551935A5 (https=) 2024-12-04

Family

ID=78844686

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533733A Pending JP2023551935A (ja) 2020-12-02 2021-11-30 Ｉｌ－７結合タンパク質および医学的療法におけるそれらの使用

Country Status (15)

Country Link
US (3) US11802150B2 (https=)
EP (1) EP4255928A1 (https=)
JP (1) JP2023551935A (https=)
KR (1) KR20230098288A (https=)
CN (1) CN116547002A (https=)
AR (1) AR124286A1 (https=)
AU (1) AU2021391493C1 (https=)
CA (1) CA3199648A1 (https=)
CL (1) CL2023001556A1 (https=)
CO (1) CO2023007851A2 (https=)
IL (1) IL303134A (https=)
MX (1) MX2023006294A (https=)
PH (1) PH12023551170A1 (https=)
TW (1) TWI821804B (https=)
WO (1) WO2022117526A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023227641A1 (en) * 2022-05-27 2023-11-30 Glaxosmithkline Intellectual Property Development Limited Use of tnf-alpha binding proteins and il-7 binding proteins in medical treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013512258A (ja) * 2009-11-30 2013-04-11 ヤンセン バイオテツク，インコーポレーテツド 除去されたエフェクター機能を伴う抗体Ｆｃ突然変異

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
AU2005269759A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013512258A (ja) * 2009-11-30 2013-04-11 ヤンセン バイオテツク，インコーポレーテツド 除去されたエフェクター機能を伴う抗体Ｆｃ突然変異

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANAL. CHEM., vol. 91, no. 24, JPN6025043778, 2019, pages 15709 - 15717, ISSN: 0005715611 *
JOURNAL OF AUTOIMMUNITY, vol. 45, JPN6025043774, 2013, pages 40 - 48, ISSN: 0005715608 *
JOURNAL OF EXPERIMENTAL MEDICINE, vol. 178, JPN6025043777, 1993, pages 257 - 264, ISSN: 0005715610 *
JOURNAL OF EXPERIMENTAL MEDICINE, vol. 198, no. 12, JPN6025043776, 2003, pages 1797 - 1806, ISSN: 0005715609 *
THE JOURNAL OF IMMUNOLOGY, vol. 190, JPN6025043773, 2013, pages 5256 - 5266, ISSN: 0005715607 *

Also Published As

Publication number Publication date
CN116547002A (zh) 2023-08-04
AU2021391493A1 (en) 2023-06-08
IL303134A (en) 2023-07-01
US11802150B2 (en) 2023-10-31
AU2021391493A9 (en) 2024-05-23
AU2021391493C1 (en) 2026-04-16
AR124286A1 (es) 2023-03-15
US20240025988A1 (en) 2024-01-25
CL2023001556A1 (es) 2023-11-10
MX2023006294A (es) 2023-06-13
KR20230098288A (ko) 2023-07-03
EP4255928A1 (en) 2023-10-11
TWI821804B (zh) 2023-11-11
PH12023551170A1 (en) 2024-01-22
WO2022117526A1 (en) 2022-06-09
US20240425581A1 (en) 2024-12-26
AU2021391493B2 (en) 2025-10-30
US12122828B2 (en) 2024-10-22
US20220169717A1 (en) 2022-06-02
TW202237183A (zh) 2022-10-01
CO2023007851A2 (es) 2023-06-30
CA3199648A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
JP7554247B2 (ja) 抗ｔｒｅｍ２抗体及びその使用方法
US12180288B2 (en) Antibodies to canine interleukin-4 receptor alpha
US20210332119A1 (en) Binding members to tnf alpha
KR102073034B1 (ko) 항cxcr3 항체
TWI678376B (zh) 經改良之Ａβ原纖維結合抗體
AU2015244025B2 (en) Binding molecules specific for IL-21 and uses thereof
KR102036938B1 (ko) 뇌에서 상승된 수준의 α-시누클레인을 진단하기 위한 항-α-시누클레인 항체의 용도
TW201542589A (zh) 偵測人類ｐｅｒｉｏｓｔｉｎ之新穎分析法
US20240425581A1 (en) IL-7 Binding Proteins and Their Use in Medical Therapy
US20150355199A1 (en) Agents, kits and methods for complement factor h-related protein 1 detection
EP4433167A1 (en) Novel molecules for therapy and diagnosis
TW202328191A (zh) 使用her3抗原結合分子的癌症之治療及預防
EP3740503A1 (en) Compounds and methods targeting interleukin-19
TW202413441A (zh) TNF-α結合蛋白及IL-7結合蛋白於醫藥治療之用途
EA044914B1 (ru) Способы улучшения ответа на лечение с помощью антитела к lif у индивидуумов, страдающих от рака
BR112016029734B1 (pt) Anticorpo isolado ou fragmento de ligação ao antígeno deste e uso do mesmo, composição farmacêutica e método para detecção de níveis de expressão de il-21 em uma amostra

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241126

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260428